Fulcrum Therapeutics (NASDAQ:FULC) Shareholders Have Endured a 77% Loss From Investing in the Stock Three Years Ago

Yahoo FinanceDec 20 01:07

Subdued Growth No Barrier To Fulcrum Therapeutics, Inc. (NASDAQ:FULC) With Shares Advancing 32%

Simply Wall StDec 15 20:23

Fulcrum Therapeutics (FULC) Upgraded to Buy: Here's Why

Yahoo FinanceNov 29 01:00

Fulcrum Therapeutics to Participate in Upcoming December Conferences

GlobeNewswireNov 27 05:05

Analysts' Opinions Are Mixed on These Healthcare Stocks: Adaptimmune Therapeutics (ADAP), Fulcrum Therapeutics (FULC) and Immunic (IMUX)

TipRanksNov 19 15:20 · Ratings

Fulcrum Therapeutics Slides As Insider Purchases Lose Another US$362k

Simply Wall StNov 16 21:18